Lee J, Koom WS, Byun HK, et al. - Researchers examined if in patients receiving systemic treatment for metastatic colorectal cancer (mCRC), oligoprogressive or oligopersistent disease could be safely and effectively managed using metastasis-directed radiotherapy (MRT).

• Among 4,157 included patients with mCRC who received 5-fluorouracil, leucovorin, and oxaliplatin; 5-fluorouracil, leucovorin, and irinotecan; and/or capecitabine chemotherapy, MRT was administered to limited lesion sites in 91 (2%) patients (55 oligoprogressive and 36 oligopersistent) during systemic treatment following a period of treatment response.

• Based on outcomes, researchers suggest that patients with oligoprogressive or oligopersistent mCRC may be safely administered MRT in conjunction with systemic treatment to enhance the benefit of systemic therapy, and to prolong the time to change to systemic therapy.